PALB2 Biallelic Inactivation

CI-VAR-00000264Explore in graph →CIViC 532

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm1
PALB2 Biallelic Inactivation	Mitomycin	Predictive	C	Supports Sensitivity Response	4	accepted	EID1305 In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mito… (full text at CIViC) PMID 21135251 · Villarroel et al., 2011 · Open in CIViC	civic
Malignant Prostate Neoplasm1
PALB2 Biallelic Inactivation	Olaparib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1963 From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.